Publications
[74] Duan H, Zhang C, Zhang Z, Wang X, Zhang J, Yang L, He F, Mao L, Yang L, Pan Z, Yin F, Han R, Wang W, Pan D, Xiao W, Peng J. (2025) Gene Therapy with covalently-closed-end AAV vector for Spinal Muscular Atrophy. Molecular Therapy doi: 10.1016/j.ymthe.2025.06.028. Full Text
[73] Herzog CR*, Zhang J*, Feng X*, Dang TT, Yu X, Huang J, Fang F, Gao H, Yu X, Wang Y, Han R, Liu Y, Cornetta K, Xiao W, Xu W (2025) Bioinformatic analysis of the genetic basis of differential AAV production capability of 293 variants. Human Gene Therapy doi: 10.1089/hum.2025.002. Full Text
[72] Liu D, Cao D, Han R*. (2025) Recent advances in therapeutic gene editing technologies. Molecular Therapy doi: 10.1016/j.ymthe.2025.03.026. Full Text
[71] Li S, Zhang C, Han R*. (2025) An oversized AAV8 vector to deliver CPS1. Molecular Therapy - Nucleic Acids 36: 102504. Full Text
[70] Koike T, Koike Y, Guo Y, Yang D, Song J, Xu J, Zhao X, Zhu T, Li R, Wen B, Sun D, Rom O, Han R, Fan J, Garcia-Barrio MT, Zhang J, Chen YE. (2025) IDOL Deficiency Inhibits Cholesterol-Rich Diet-Induced Atherosclerosis in Rabbits. Arteriosclerosis, Thrombosis, and Vascular Biology doi: 10.1161/ATVBAHA.125.322417. Full Text
[69] Tsai L-K, Han R, Yang D, Chen YE, Zhang J, Xu J (2025) Promotion or inhibition? This is a question in gene editing. Molecular Therapy doi: 10.1016/j.ymthe.2025.01.014. Full Text
[68] Tran NT, Han R*. (2024) Rapidly Evolving Genome and Epigenome Editing Technologies. Molecular Therapy 32: 2803-2806. Full Text
[67] Zhou R, Zhang C, Xiao W, Herzog RW, Han R*. (2024) Systemic Delivery of Full-Length Dystrophin in Duchenne Muscular Dystrophy Mice. Nature Communications 15(1): 6141. Full Text
[66] Gandhi S*, Sweeney HL, Hart CC, Han R, Perry CGR* (2024) Mitochondria in Duchenne Muscular Dystrophy-induced Cardiomyopathy: A Prospective Therapeutic Target to Improve Treatment Response. Cells 13(14): 1168. Full Text
[65] Li S, Han R*. (2024) Targeting miR-25 to Alleviate DMD-Related Muscle Dysfunction. Molecular Therapy - Nucleic Acids 35: 102238. Full Text
[64] Zhang C, Zhou Y, Han R*. (2024) Base editing in humanized dystrophic mice. Molecular Therapy - Nucleic Acids 35: 102185. Full Text
[63] Han R*. (2024) Hit-and-run epigenome editing durably lowers cholesterol in mice. Molecular Therapy 32: 1190-1191. Full Text
[62] Han R*. (2023) First in vivo base-editing trial shows promise. Molecular Therapy 32: 1-2. Full Text
[61] Li H, Wang P, Zhang C, Zuo Y, Zhou Y, Han R*. (2023) Defective BVES-mediated feedback control of cAMP in muscular dystrophy. Nature Communications 14: 1785. Full Text
[60] Zuo Y, Zhang C, Zhou Y, Li H, Xiao W, Herzog RW, Xu J, Zhang J, Chen EY, Han R*. (2023) Liver-specific in vivo base editing of Angptl3 via AAV delivery efficiently lowers blood lipid levels in mice. Cell & Bioscience 13: 109. Full Text
[59] Wang P, Li H, Zhu M, Han RY, Guo S, Han R*. (2022) Correction of DMD in human iPSC-derived cardiomyocytes by base editing-induced exon skipping. Molecular Therapy - Methods & Clinical Development 28: 40-50. Full Text
[58] Li H, Wang P, Hsu E, Pinckard KM, Stanford KI and Han R*. (2022) Systemic AAV9.BVES Delivery Ameliorates Muscular Dystrophy in a Mouse Model of LGMDR25. Molecular Therapy 31(2): 398-408. Full Text
[57] Zou X, Ouyang H, Lin F, Zhang H, Yang Y, Pang D, Han R*, Tang X*. (2022) MYBPC3 deficiency in cardiac fibroblasts drives their activation and contributes to fibrosis. Cell Death & Disease 13(11): 948. Full Text
[56] Li H, Zhang L, Zhang L and Han R*. (2022) Autophagy in striated muscle diseases. Frontiers in Cardiovascular Medicine doi: 10.3389/fcvm.2022.1000067. Full Text
[55] Zhang M, Urabe G, Ozer HG, Xie X, Webb A, Shirasu T, Li J, Han R, Kent KC, Wang B and Guo LW. (2022) Angioplasty induces epigenomic remodeling in injured arteries. Life Science Alliance 5: e202101114. Full Text
| Next | Last |